Anti-hepatic Fibrosis Effect of Ammonium Glycyrrhetate Combined Oxymatrine and Its Mechanism

MENG Ya-kun; CHAI Xuan; ZHAO Hong-wei; ZHANG Zhen-fang; ZHANG Cong-en; CUI He-rong; WANG Ya; LI Guang-quan; BAI Zhao-fang; XIAO Xiao-he

doi:10.13422/j.cnki.syfjx.2016210110

您当前的位置：

首页 >

文章列表页 >

Anti-hepatic Fibrosis Effect of Ammonium Glycyrrhetate Combined Oxymatrine and Its Mechanism

更新时间：2024-01-04

- Anti-hepatic Fibrosis Effect of Ammonium Glycyrrhetate Combined Oxymatrine and Its Mechanism
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 22, Issue 21, Pages: 110-115(2016)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2016210110
  CLC： R285.5
- Published：2016
- 稿件说明：
移动端阅览
MENG Ya-kun, CHAI Xuan, ZHAO Hong-wei, et al. Anti-hepatic Fibrosis Effect of Ammonium Glycyrrhetate Combined Oxymatrine and Its Mechanism[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(21): 110-115.
DOI：

MENG Ya-kun, CHAI Xuan, ZHAO Hong-wei, et al. Anti-hepatic Fibrosis Effect of Ammonium Glycyrrhetate Combined Oxymatrine and Its Mechanism[J]. Chinese journal of experimental traditional medical formulae, 2016, 22(21): 110-115. DOI： 10.13422/j.cnki.syfjx.2016210110.

摘要

目的：研究甘草酸铵联合苦参素对四氯化碳（CCl4）导致的大鼠肝纤维化的抑制作用，并探讨其相关机制。方法： SD大鼠随机分为6组，每组10只，分别为正常组，模型组，秋水仙碱阳性药组（2 mg·kg-1），甘草酸铵组（15 mg·kg-1），苦参素组（30 mg·kg-1），甘草酸铵联合苦参素（15 mg·kg-1+30 mg·kg-1）组，除正常组外，其余各组均采用CCl4诱导的大鼠肝纤维化模型，治疗组分别给予等同于临床剂量的相应药物，正常组和模型组给予生理盐水进行对照。通过检测血清中丙氨酸氨基转移酶（ALT），天门冬氨酸氨基转移酶（AST）及肝组织中羟脯氨酸（Hyp）和观察肝组织病理切片来评价肝纤维化程度，检测血清中白细胞介素6（IL-6），乙酰胆碱酯酶（AchE），高迁移率族蛋白1（HMGB1），内毒素（LPS）变化趋势。结果：与正常组比较，模型组大鼠血清ALT，AST，IL-6，AchE，LPS，HMGB1水平及肝组织Hyp含量明显升高（P<0.01），模型组肝组织病变较为明显；与正常组比较模型组胶原面积显著增加；与模型组比较，治疗组明显降低大鼠血清中ALT，AST，IL-6，AchE，LPS，HMGB1水平及肝组织Hyp含量（P<0.05），肝组织病变明显减轻，胶原面积明显降低；同时苦参素组与模型组比AchE显著降低（P<0.05），联合用药与苦参素组比AchE显著升高（P<0.05）。结论：甘草酸铵联合苦参素可抗由CCl4诱导的大鼠肝纤维化，抗肝纤维化主要可能是通过减少大鼠体内LPS的含量和降低IL-6，HMGB1的表达来实现的，并且联合用药可改善临床上单独使用苦参素降低乙酰胆碱酯酶下降的情况。

Abstract

Objective: To research the anti-hepatic fibrosis effect of ammonium glycyrrhetate combined oxymatrine in hepatic fibrosis rat induced by CCl4 and its mechanism. Method: SD rats were randomly divided into six groups

namely normal group

model group

colchicine positive group (2 mg·kg-1)

ammonium glycyrrhetate group (15 mg·kg-1)

oxymatrine group (30 mg·kg-1)

ammonium glycyrrhetate combined oxymatrine group (15 mg·kg-1+30 mg·kg-1)

with 10 in each group. Except for normal group

in the remaining groups

the rat liver fibrosis model were induced by CCl4.Normal group and model group were given the saline

treatment groups were administered with the corresponding drugs of equal clinical doses. Their liver fibrosis were assessed by detecting serum alanine transaminase (ALT)

aspertate aminotransferase (AST) and liver hydroxyproline (Hyp) and observing liver tissue pathology biopsy. Besides

serum interleukin-6(IL-6)

acetylcholin esterase (AchE)

high mobility group protein 1 (HMGB1)

and lipopolysaccharide (LPS) were also detected. Result: Compared with model group

model group showed remarkable increases in ALT

AST

IL-6

AchE

LPS

HMGB1 and liver Hyp (P<0.01)

significant liver tissue pathological changes

and notable expansion in collagen area. Compared with model group

ALT

AST and IL-6

AchE

LPS

HMGB1 levels and liver Hyp significantly decreased in treatment group (P<0.05)

At the same time

compared with model group

oxymatrine group showed obvious decrease in the expression of AchE (P<0.05)

and combination group showed a higher AchE expressions than oxymatrine group (P<0.05)

and significant alleviation in liver tissue pathological changes and collagen area. Conclusion: Ammonium glycyrrhetate combined oxymatrine can inhibit CCl4-induced liver fibrosis in rats by reducing the levels of LPS and the expression of IL-6

HMGB1.The combined administration can improve the clinical effect in declining acetyl cholinesterase by using oxymatrine alone.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Mechanism and Combination Therapy of Berberine in Treatment of Nonalcoholic Fatty liver Disease：A Review

Clinical Efficacy of Gandou Fumu Granules in Intervention of Liver Fibrosis in WD Patients with Phlegm and Blood Stasis Syndrome and Effect on Cuproptosis-related Indicators

Gandouling Regulates PI3K/Akt/mTOR Autophagy Signaling Pathway via LncRNA H19 for Treatment of Wilson Disease Liver Fibrosis

Mechanism of Shugan Huazheng Prescription Against Liver Fibrosis Based on HIF-1α/VEGF/TGF-β₁ Pathway

Effect of Gandou Fumu Decoction on Autophagy in Mice with Liver Fibrosis in Wilson's Disease by Regulating Expression of miR-29b-3p/ULK1

Related Author

WANG Xiaojie

ZHANG Heng

LIU Sutong

ZHANG Lihui

ZHAO Wenxia

WANG Fei

JIANG Zhenzhen

CHEN Yimin

Related Institution

Henan General Hospital

The First Affiliated Hospital of Henan University of Chinese Medicine

The First Clinical Medical College of Henan University of Chinese Medicine

The First Affiliated Hospital of Anhui University of Chinese Medicine

Graduate School of Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰